172 related articles for article (PubMed ID: 15809480)
21. Use of laxative-augmented contrast medium in the evaluation of colorectal foci at FDG PET.
Chen YK; Chen JH; Tsui CC; Chou HH; Cheng RH; Chiu JS
Radiology; 2011 May; 259(2):525-33. PubMed ID: 21406631
[TBL] [Abstract][Full Text] [Related]
22. Performance of integrated FDG-PET/contrast-enhanced CT in the staging and restaging of colorectal cancer: comparison with PET and enhanced CT.
Dirisamer A; Halpern BS; Flöry D; Wolf F; Beheshti M; Mayerhoefer ME; Langsteger W
Eur J Radiol; 2010 Feb; 73(2):324-8. PubMed ID: 19200683
[TBL] [Abstract][Full Text] [Related]
23. Routine (18)F-FDG PET preoperative staging of colorectal cancer: comparison with conventional staging and its impact on treatment decision making.
Kantorová I; Lipská L; Bêlohlávek O; Visokai V; Trubaĉ M; Schneiderová M
J Nucl Med; 2003 Nov; 44(11):1784-8. PubMed ID: 14602860
[TBL] [Abstract][Full Text] [Related]
24. Detection of resectable recurrences in colorectal cancer patients with 2-[18F]fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography.
Peng NJ; Hu C; King TM; Chiu YL; Wang JH; Liu RS
Cancer Biother Radiopharm; 2013; 28(6):479-87. PubMed ID: 23713869
[TBL] [Abstract][Full Text] [Related]
25. Correction of an image size difference between positron emission tomography (PET) and computed tomography (CT) improves image fusion of dedicated PET and CT.
Vogel WV; van Dalen JA; Schinagl DA; Kaanders JH; Huisman H; Corstens FH; Oyen WJ
Nucl Med Commun; 2006 Jun; 27(6):515-9. PubMed ID: 16710106
[TBL] [Abstract][Full Text] [Related]
26. Role of 2-[18F] fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography in the post-therapy surveillance of breast cancer.
Chang HT; Hu C; Chiu YL; Peng NJ; Liu RS
PLoS One; 2014; 9(12):e115127. PubMed ID: 25517451
[TBL] [Abstract][Full Text] [Related]
27. Established, emerging and future roles of PET/CT in the management of colorectal cancer.
Herbertson RA; Scarsbrook AF; Lee ST; Tebbutt N; Scott AM
Clin Radiol; 2009 Mar; 64(3):225-37. PubMed ID: 19185652
[TBL] [Abstract][Full Text] [Related]
28. PET/CT using 18F-FDG in suspected lung cancer recurrence: diagnostic value and impact on patient management.
Keidar Z; Haim N; Guralnik L; Wollner M; Bar-Shalom R; Ben-Nun A; Israel O
J Nucl Med; 2004 Oct; 45(10):1640-6. PubMed ID: 15471827
[TBL] [Abstract][Full Text] [Related]
29. Diagnosis supporting algorithm for lymph node metastases from colorectal carcinoma on 18F-FDG PET/CT.
Inoue K; Sato T; Kitamura H; Ito M; Tsunoda Y; Hirayama A; Kurosawa H; Tanaka T; Fukushi M; Moriyama N; Fujii H
Ann Nucl Med; 2008 Jan; 22(1):41-8. PubMed ID: 18250986
[TBL] [Abstract][Full Text] [Related]
30. Clinical impact of integrated PET/CT on the management of suspected cervical cancer recurrence.
Chung HH; Jo H; Kang WJ; Kim JW; Park NH; Song YS; Chung JK; Kang SB; Lee HP
Gynecol Oncol; 2007 Mar; 104(3):529-34. PubMed ID: 17049971
[TBL] [Abstract][Full Text] [Related]
31. Diagnostic Value of (18)F-FDG PET/CT in Detecting Local Recurrent Colorectal Cancer: A Pooled Analysis of 26 Individual Studies.
Yu T; Meng N; Chi D; Zhao Y; Wang K; Luo Y
Cell Biochem Biophys; 2015 Jun; 72(2):443-51. PubMed ID: 25737131
[TBL] [Abstract][Full Text] [Related]
32. A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer.
Kauhanen SP; Komar G; Seppänen MP; Dean KI; Minn HR; Kajander SA; Rinta-Kiikka I; Alanen K; Borra RJ; Puolakkainen PA; Nuutila P; Ovaska JT
Ann Surg; 2009 Dec; 250(6):957-63. PubMed ID: 19687736
[TBL] [Abstract][Full Text] [Related]
33. FDG PET and PET/CT for colorectal cancer.
Delbeke D; Martin WH
Methods Mol Biol; 2011; 727():77-103. PubMed ID: 21331930
[TBL] [Abstract][Full Text] [Related]
34. 18F-FDG PET and CT/MRI in oral cavity squamous cell carcinoma: a prospective study of 124 patients with histologic correlation.
Ng SH; Yen TC; Liao CT; Chang JT; Chan SC; Ko SF; Wang HM; Wong HF
J Nucl Med; 2005 Jul; 46(7):1136-43. PubMed ID: 16000282
[TBL] [Abstract][Full Text] [Related]
35. Integrated contrast-enhanced diagnostic whole-body PET/CT as a first-line restaging modality in patients with suspected metastatic recurrence of breast cancer.
Dirisamer A; Halpern BS; Flöry D; Wolf F; Beheshti M; Mayerhoefer ME; Langsteger W
Eur J Radiol; 2010 Feb; 73(2):294-9. PubMed ID: 19181468
[TBL] [Abstract][Full Text] [Related]
36. The role of 18F-fluoro-deoxy-glucose positron emission tomography (FDG-PET) in the management of patients with colorectal cancer.
Pelosi E; Deandreis D
Eur J Surg Oncol; 2007 Feb; 33(1):1-6. PubMed ID: 17126522
[TBL] [Abstract][Full Text] [Related]
37. Correlation between serum CEA level and metabolic volume as determined by FDG PET in postoperative patients with recurrent colorectal cancer.
Choi MY; Lee KM; Chung JK; Lee DS; Jeong JM; Park JG; Kim JH; Lee MC
Ann Nucl Med; 2005 Apr; 19(2):123-9. PubMed ID: 15909492
[TBL] [Abstract][Full Text] [Related]
38. Automated 3-dimensional registration of stand-alone (18)F-FDG whole-body PET with CT.
Slomka PJ; Dey D; Przetak C; Aladl UE; Baum RP
J Nucl Med; 2003 Jul; 44(7):1156-67. PubMed ID: 12843232
[TBL] [Abstract][Full Text] [Related]
39. The role of 18F-FDG PET/CT for initial staging of nasal type natural killer/T-cell lymphoma: a comparison with conventional staging methods.
Moon SH; Cho SK; Kim WS; Kim SJ; Chan Ahn Y; Choe YS; Lee KH; Kim BT; Choi JY
J Nucl Med; 2013 Jul; 54(7):1039-44. PubMed ID: 23658217
[TBL] [Abstract][Full Text] [Related]
40. Value of fusion of PET and MRI for staging of endometrial cancer: comparison with ¹⁸F-FDG contrast-enhanced PET/CT and dynamic contrast-enhanced pelvic MRI.
Kitajima K; Suenaga Y; Ueno Y; Kanda T; Maeda T; Takahashi S; Ebina Y; Miyahara Y; Yamada H; Sugimura K
Eur J Radiol; 2013 Oct; 82(10):1672-6. PubMed ID: 23727380
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
